Gene: MEF2C

4208
C5DELq14.3|DEL5q14.3
myocyte enhancer factor 2C
protein-coding
5q14.3
Ensembl:ENSG00000081189 MIM:600662 Vega:OTTHUMG00000162634 UniprotKB:Q06413
NG_023427.1
PubMed
0   ANCO-SNPs
ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.267e-1 (AD)  2.044e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DLGAP10.968
GABRB20.962
LDB20.961
GABRA10.959
RGS40.958
OPCML0.957
FAM81A0.956
RIMS30.956
EPHA40.955
ENC10.955

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ACAP1-0.545
HEY2-0.512
RAI14-0.493
SNHG18-0.492
LRAT-0.489
SH2D1A-0.483
WWTR1-0.481
RAB13-0.481
ARHGEF5-0.476
DNAI2-0.473

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of MEF2C mRNA"27291303
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in increased expression of MEF2C mRNA"19114083
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in increased expression of MEF2C mRNA"20206263
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of MEF2C mRNA"18648102
C0909424-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Phenylephrine results in increased expression of MEF2C mRNA]10737771
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C011651acadesineacadesine results in decreased expression of MEF2C mRNA15864539
D000082AcetaminophenAcetaminophen results in increased expression of MEF2C mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of MEF2C mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MEF2C gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of MEF2C mRNA19770486
D013196DihydrotestosteroneDihydrotestosterone results in increased expression of MEF2C mRNA18007998
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of MEF2C mRNA21298039
D000638AmiodaroneAmiodarone results in increased expression of MEF2C mRNA19774075
D001151ArsenicArsenic affects the expression of MEF2C mRNA18414638
D001151ArsenicArsenic affects the methylation of MEF2C gene25304211
D001280AtrazineAtrazine results in decreased expression of MEF2C mRNA25929836
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MEF2C mRNA20064835
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MEF2C mRNA21569818|2222880
D004958EstradiolEstradiol results in increased expression of MEF2C mRNA23094148
D004958EstradiolIGF1R mutant form inhibits the reaction [Estradiol results in increased expression of MEF2C mRNA]23094148
C006780bisphenol Abisphenol A results in increased expression of MEF2C mRNA18007998
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MEF2C mRNA28628672
C006780bisphenol Abisphenol A results in increased expression of MEF2C mRNA25181051
C487049BXL628BXL628 results in decreased expression of MEF2C mRNA16003237
D002110CaffeineCaffeine results in increased expression of MEF2C mRNA25093688
D002110CaffeineCaffeine results in increased expression of MEF2C protein25093688
D002110CaffeineDantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]25093688
D002110CaffeineDantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein]25093688
D002185CannabidiolCannabidiol results in decreased expression of MEF2C mRNA21542829
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of MEF2C mRNA17484886
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in increased expression of MEF2C mRNA16934159
D002737ChloropreneChloroprene results in decreased expression of MEF2C mRNA23125180
D004390ChlorpyrifosChlorpyrifos results in increased expression of MEF2C mRNA20350560
C031180chrysenechrysene results in increased expression of MEF2C mRNA26377693
D003474CurcuminCurcumin results in decreased expression of MEF2C mRNA27237783
D016572CyclosporineCyclosporine results in increased expression of MEF2C mRNA20106945
D003620DantroleneDantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]25093688
D003620DantroleneDantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein]25093688
C014347decitabinedecitabine results in increased expression of MEF2C mRNA19151715
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MEF2C mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of MEF2C mRNA17361019|2126653
D004121Dimethyl SulfoxideDimethyl Sulfoxide results in decreased expression of MEF2C mRNA22105179
D004121Dimethyl SulfoxideDimethyl Sulfoxide results in increased expression of MEF2C mRNA22105179
D004317DoxorubicinDoxorubicin results in decreased expression of MEF2C mRNA11073966
D004317DoxorubicinEP300 inhibits the reaction [Doxorubicin results in decreased expression of MEF2C mRNA]11073966
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of MEF2C mRNA23649840
C000499ferric oxideferric oxide analog results in decreased expression of MEF2C mRNA25086211
D005557FormaldehydeFormaldehyde results in decreased expression of MEF2C mRNA23649840
C081021Go 6976Go 6976 inhibits the reaction [Phenylephrine results in increased activity of MEF2C protein]19124542
D006861Hydrogen Peroxide[SNCA gene mutant form results in increased susceptibility to Hydrogen Peroxide] which results in increased metabolism of MEF2C protein24290359
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of MEF2C mRNA23562911
D006861Hydrogen PeroxideHydrogen Peroxide results in increased expression of MEF2C mRNA23562911
C056599icariinicariin affects the localization of MEF2C protein18423597
C056599icariinicariin results in increased expression of MEF2C mRNA18423597
C056599icariinSB 203580 inhibits the reaction [icariin affects the localization of MEF2C protein]18423597
C056599icariinSB 203580 inhibits the reaction [icariin results in increased expression of MEF2C mRNA]18423597
C056599icariinU 0126 inhibits the reaction [icariin affects the localization of MEF2C protein]18423597
C056599icariinU 0126 inhibits the reaction [icariin results in increased expression of MEF2C mRNA]18423597
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MEF2C mRNA28628672
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MEF2C mRNA25613284
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of MEF2C mRNA28628672
D007545IsoproterenolIsoproterenol results in decreased expression of MEF2C mRNA20003209
D007555IsoxazolesIsoxazoles results in increased expression of MEF2C mRNA24290359
C063302KN 62KN 62 inhibits the reaction [Phenylephrine results in increased expression of MEF2C mRNA]10737771
D007854LeadLead affects the expression of MEF2C mRNA28903495
D058185Magnetite Nanoparticles[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of MEF2C mRNA21641980
D008344Maneb[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein24290359
D008344Maneb[Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein24290359
D008687MetforminMetformin results in increased expression of MEF2C mRNA15864539
D008727MethotrexateMethotrexate affects the expression of MEF2C mRNA18502557
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of MEF2C mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of MEF2C mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of MEF2C mRNA"19285098
C008493methylselenic acidmethylselenic acid results in increased expression of MEF2C mRNA18548127
D015735MifepristoneMifepristone results in decreased expression of MEF2C mRNA25972201
D009151Mustard GasMustard Gas results in increased expression of MEF2C mRNA15674843
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of MEF2C mRNA19812364
D009532NickelNickel results in increased expression of MEF2C mRNA18922574
C029938nickel sulfatenickel sulfate results in decreased expression of MEF2C mRNA16166746
D009538NicotineNicotine affects the expression of MEF2C mRNA20426880
C007350nitrofennitrofen results in decreased expression of MEF2C mRNA18280291
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MEF2C mRNA27935865
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of MEF2C mRNA25729387
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of MEF2C mRNA26272509
D010269Paraquat[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein24290359
D010269Paraquat[Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein24290359
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of MEF2C mRNA23562911|2617826
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of MEF2C protein26178269
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in increased expression of MEF2C mRNA23562911
D010656PhenylephrineGo 6976 inhibits the reaction [Phenylephrine results in increased activity of MEF2C protein]19124542
D010656PhenylephrinePhenylephrine results in increased activity of MEF2C protein19124542
D010656Phenylephrine4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Phenylephrine results in increased expression of MEF2C mRNA]10737771
D010656PhenylephrineKN 62 inhibits the reaction [Phenylephrine results in increased expression of MEF2C mRNA]10737771
D010656PhenylephrinePhenylephrine results in increased expression of MEF2C mRNA10737771
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of MEF2C mRNA26272509
D010705PhosgenePhosgene affects the expression of MEF2C mRNA16300373
D010862PilocarpinePilocarpine results in increased expression of MEF2C mRNA18949272
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MEF2C mRNA27935865
C006253pirinixic acidpirinixic acid results in decreased expression of MEF2C mRNA18445702
C006253pirinixic acidpirinixic acid results in increased expression of MEF2C mRNA17951219
C059514resveratrolresveratrol results in increased expression of MEF2C mRNA12002526
C059514resveratrolresveratrol results in decreased expression of MEF2C mRNA22610192
D015474IsotretinoinIsotretinoin results in increased expression of MEF2C mRNA20436886
C116926rofecoxibrofecoxib affects the expression of MEF2C mRNA17070997
C093642SB 203580SB 203580 inhibits the reaction [icariin affects the localization of MEF2C protein]18423597
C093642SB 203580SB 203580 inhibits the reaction [icariin results in increased expression of MEF2C mRNA]18423597
D012822Silicon DioxideSilicon Dioxide results in decreased expression of MEF2C mRNA19073995
D012834SilverSilver results in decreased expression of MEF2C mRNA27131904
D012906SmokeSmoke affects the expression of MEF2C mRNA23693141
C009277sodium arsenatesodium arsenate results in increased expression of MEF2C mRNA21795629
C017947sodium arsenitesodium arsenite affects the localization of MEF2C protein20965206
C017947sodium arsenitesodium arsenite results in decreased expression of MEF2C mRNA20965206
C017947sodium arsenitesodium arsenite results in decreased expression of MEF2C protein20965206
D013096SpermineSpermine results in increased expression of MEF2C mRNA18673383
D013311StreptozocinSOD1 protein inhibits the reaction [Streptozocin results in decreased expression of MEF2C mRNA]27629361
D013311StreptozocinStreptozocin results in decreased expression of MEF2C mRNA27629361
D004113Succimer[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of MEF2C mRNA21641980
C020806tetrabromobisphenol Atetrabromobisphenol A results in decreased expression of MEF2C mRNA25172293
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MEF2C mRNA24058054|2637764
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MEF2C mRNA19465110
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MEF2C mRNA25613284
C009495titanium dioxidetitanium dioxide results in increased expression of MEF2C mRNA23557971
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of MEF2C mRNA27237783
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of MEF2C mRNA25729387
D014118Toxins, Biological"Toxins, Biological affects the expression of MEF2C mRNA"19682533
D014212TretinoinTretinoin results in decreased expression of MEF2C mRNA23724009
D014212TretinoinTretinoin results in increased expression of MEF2C mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of MEF2C mRNA24935251|2627250
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of MEF2C mRNA19042947
C113580U 0126U 0126 inhibits the reaction [icariin affects the localization of MEF2C protein]18423597
C113580U 0126U 0126 inhibits the reaction [icariin results in increased expression of MEF2C mRNA]18423597
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of MEF2C mRNA19101580|2317975
D014635Valproic AcidValproic Acid results in increased expression of MEF2C mRNA27237783
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of MEF2C gene25560391
C025643vinclozolinvinclozolin affects the expression of MEF2C mRNA19015723
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEF2C mRNA"27188386
C111237vorinostatvorinostat results in increased expression of MEF2C mRNA26272509
D014873Water PollutantsWater Pollutants results in increased expression of MEF2C mRNA23591932

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IDA8455629  
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IBA21873635  
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IEA-  
GO:0000980RNA polymerase II distal enhancer sequence-specific DNA binding-IEA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISS21610032  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0000983transcription factor activity, RNA polymerase II core promoter sequence-specific DNA binding-IDA8455629  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IBA21873635  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IDA15486975  
GO:0001102RNA polymerase II activating transcription factor binding-IBA21873635  
GO:0001205transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific DNA binding-IBA21873635  
GO:0001205transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific DNA binding-IEA-  
GO:0003680AT DNA binding-IDA15486975  
GO:0003682chromatin binding-IEA-  
GO:0003700DNA-binding transcription factor activity-IDA16043483  
GO:0005515protein binding-IPI15486975  16043483  16510869  18588859  21556048  
GO:0033613activating transcription factor binding-IPI11160896  
GO:0042826histone deacetylase binding-IBA21873635  
GO:0042826histone deacetylase binding-IEA-  
GO:0044212transcription regulatory region DNA binding-ISS-  
GO:0046982protein heterodimerization activity-IPI9858528  
GO:0071837HMG box domain binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IMP18079734  
GO:0000165MAPK cascade-IDA9858528  
GO:0000165MAPK cascade-IMP11160896  
GO:0001568blood vessel development-ISS-  
GO:0001649osteoblast differentiation-ISS-  
GO:0001764neuron migration-ISS-  
GO:0001782B cell homeostasis-ISS-  
GO:0001947heart looping-ISS-  
GO:0001958endochondral ossification-ISS-  
GO:0001974blood vessel remodeling-ISS-  
GO:0002062chondrocyte differentiation-ISS-  
GO:0002467germinal center formation-ISS-  
GO:0002634regulation of germinal center formation-ISS-  
GO:0003138primary heart field specification-ISS-  
GO:0003139secondary heart field specification-ISS-  
GO:0003151outflow tract morphogenesis-ISS-  
GO:0003185sinoatrial valve morphogenesis-ISS-  
GO:0003211cardiac ventricle formation-ISS-  
GO:0006355regulation of transcription, DNA-templated-IDA24008018  
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0006915apoptotic process-IEA-  
GO:0006959humoral immune response-ISS-  
GO:0007399nervous system development-TAS8455629  
GO:0007507heart development-IEP10458488  
GO:0007507heart development-ISS-  
GO:0007507heart development-NAS15486975  
GO:0007517muscle organ development-TAS8455629  
GO:0007519skeletal muscle tissue development-ISS-  
GO:0007521muscle cell fate determination-ISS-  
GO:0007611learning or memory-ISS-  
GO:0010628positive regulation of gene expression-IDA9857019  21556048  
GO:0010629negative regulation of gene expression-ISS-  
GO:0010694positive regulation of alkaline phosphatase activity-ISS-  
GO:0014033neural crest cell differentiation-ISS21610032  
GO:0014898cardiac muscle hypertrophy in response to stress-IEA-  
GO:0014902myotube differentiation-IEP8455629  
GO:0030182neuron differentiation-IEP8455629  
GO:0030182neuron differentiation-ISS-  
GO:0030220platelet formation-ISS-  
GO:0030224monocyte differentiation-IEA-  
GO:0030279negative regulation of ossification-IDA17696759  
GO:0030318melanocyte differentiation-ISS21610032  
GO:0030501positive regulation of bone mineralization-ISS-  
GO:0030890positive regulation of B cell proliferation-ISS-  
GO:0035690cellular response to drug-ISS-  
GO:0035914skeletal muscle cell differentiation-IEA-  
GO:0035984cellular response to trichostatin A-ISS-  
GO:0042100B cell proliferation-ISS-  
GO:0043523regulation of neuron apoptotic process-ISS-  
GO:0043524negative regulation of neuron apoptotic process-ISS-  
GO:0043537negative regulation of blood vessel endothelial cell migration-IGI26184978  
GO:0045652regulation of megakaryocyte differentiation-ISS-  
GO:0045663positive regulation of myoblast differentiation-IMP9770491  
GO:0045666positive regulation of neuron differentiation-ISS-  
GO:0045669positive regulation of osteoblast differentiation-ISS-  
GO:0045893positive regulation of transcription, DNA-templated-IDA17696759  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA8455629  15486975  16043483  
GO:0045944positive regulation of transcription by RNA polymerase II-IMP11160896  21556048  
GO:0046928regulation of neurotransmitter secretion-ISS-  
GO:0048167regulation of synaptic plasticity-ISS-  
GO:0048643positive regulation of skeletal muscle tissue development-IMP9770491  
GO:0048666neuron development-ISS-  
GO:0048667cell morphogenesis involved in neuron differentiation-ISS-  
GO:0048703embryonic viscerocranium morphogenesis-IEA-  
GO:0050853B cell receptor signaling pathway-ISS-  
GO:0051145smooth muscle cell differentiation-ISS-  
GO:0051149positive regulation of muscle cell differentiation-TAS-  
GO:0051963regulation of synapse assembly-ISS-  
GO:0051966regulation of synaptic transmission, glutamatergic-ISS-  
GO:0055012ventricular cardiac muscle cell differentiation-ISS-  
GO:0060021roof of mouth development-IEA-  
GO:0060025regulation of synaptic activity-ISS-  
GO:0060045positive regulation of cardiac muscle cell proliferation-ISS-  
GO:0060079excitatory postsynaptic potential-ISS-  
GO:0060297regulation of sarcomere organization-IEA-  
GO:0060536cartilage morphogenesis-IEA-  
GO:0060998regulation of dendritic spine development-ISS-  
GO:0061333renal tubule morphogenesis-ISS-  
GO:0071222cellular response to lipopolysaccharide-ISS-  
GO:0071277cellular response to calcium ion-ISS-  
GO:0071374cellular response to parathyroid hormone stimulus-IDA17696759  
GO:0071498cellular response to fluid shear stress-ISS-  
GO:0071560cellular response to transforming growth factor beta stimulus-IDA9770491  
GO:0071864positive regulation of cell proliferation in bone marrow-IEA-  
GO:0072102glomerulus morphogenesis-ISS-  
GO:0072160nephron tubule epithelial cell differentiation-ISS-  
GO:0090073positive regulation of protein homodimerization activity-ISS-  
GO:1904706negative regulation of vascular smooth muscle cell proliferation-IDA28799067  
GO:1904706negative regulation of vascular smooth muscle cell proliferation-IGI26184978  
GO:1904753negative regulation of vascular associated smooth muscle cell migration-IDA28799067  
GO:1904753negative regulation of vascular associated smooth muscle cell migration-IGI26184978  
GO:1905563negative regulation of vascular endothelial cell proliferation-IGI26184978  
GO:2000111positive regulation of macrophage apoptotic process-ISS-  
GO:2000310regulation of NMDA receptor activity-ISS-  
GO:2000311regulation of AMPA receptor activity-ISS-  
GO:2000727positive regulation of cardiac muscle cell differentiation-IDA9857019  
GO:2000987positive regulation of behavioral fear response-ISS-  
GO:2001013epithelial cell proliferation involved in renal tubule morphogenesis-ISS-  
GO:2001016positive regulation of skeletal muscle cell differentiation-IDA21556048  
GO ID GO Term Qualifier Evidence PubMed
GO:0000790nuclear chromatin-IBA21873635  
GO:0005634nucleus-IDA8455629  9770491  16510869  21170291  24008018  
GO:0005654nucleoplasm-IDA-  
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IDA8455629  
GO:0016528sarcoplasm-IEA-  
GO:0016607nuclear speck-IDA18079734  
GO:0032991protein-containing complex-IDA15486975  
GO:0043231intracellular membrane-bounded organelle-IDA-  
GO:0098794postsynapse-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
Reactome ID Reactome Term Evidence
R-HSA-1266738Developmental BiologyTAS
R-HSA-1280215Cytokine Signaling in Immune systemIEA
R-HSA-1592230Mitochondrial biogenesisTAS
R-HSA-162582Signal TransductionIEA
R-HSA-166016Toll Like Receptor 4 (TLR4) CascadeIEA
R-HSA-166058MyD88:Mal cascade initiated on plasma membraneIEA
R-HSA-166166MyD88-independent TLR4 cascade IEA
R-HSA-166520Signaling by NTRKsIEA
R-HSA-168138Toll Like Receptor 9 (TLR9) CascadeIEA
R-HSA-168142Toll Like Receptor 10 (TLR10) CascadeIEA
R-HSA-168164Toll Like Receptor 3 (TLR3) CascadeIEA
R-HSA-168176Toll Like Receptor 5 (TLR5) CascadeIEA
R-HSA-168179Toll Like Receptor TLR1:TLR2 CascadeIEA
R-HSA-168181Toll Like Receptor 7/8 (TLR7/8) CascadeIEA
R-HSA-168188Toll Like Receptor TLR6:TLR2 CascadeIEA
R-HSA-168249Innate Immune SystemIEA
R-HSA-168256Immune SystemIEA
R-HSA-168898Toll-Like Receptors CascadesIEA
R-HSA-181438Toll Like Receptor 2 (TLR2) CascadeIEA
R-HSA-1852241Organelle biogenesis and maintenanceTAS
R-HSA-187037Signaling by NTRK1 (TRKA)IEA
R-HSA-198725Nuclear Events (kinase and transcription factor activation)IEA
R-HSA-198753ERK/MAPK targetsIEA
R-HSA-2151201Transcriptional activation of mitochondrial biogenesisTAS
R-HSA-375170CDO in myogenesisTAS
R-HSA-400253Circadian ClockTAS
R-HSA-448424Interleukin-17 signalingIEA
R-HSA-449147Signaling by InterleukinsIEA
R-HSA-450282MAPK targets/ Nuclear events mediated by MAP kinasesIEA
R-HSA-450294MAP kinase activationIEA
R-HSA-525793MyogenesisTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA
R-HSA-937061TRIF(TICAM1)-mediated TLR4 signaling IEA
R-HSA-975138TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activationIEA
R-HSA-975155MyD88 dependent cascade initiated on endosomeIEA
R-HSA-975871MyD88 cascade initiated on plasma membraneIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27237783Mainstream smoke and sidestream smoke affect the cardiac differentiation of mouse embryonic stem cells discriminately. (2016 May 16)Cheng WToxicology
28199971Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population. (2017 Apr 11)Lin EOncotarget
29032150Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. (2018 Jan 30)Sundararajan TGene